UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent

ABSTRACT

The Food and Drug Administration recently cleared silver diamine fluoride for reducing tooth sensitivity. Clinical trials document arrest and prevention of dental caries by silver diamine fluoride. This off-label use is now permissible and appropriate under U.S. law. A CDT code was approved for caries arresting medicaments for 2016 to facilitate documentation and billing. We present a systematic review, clinical indications, clinical protocol and consent procedure to guide application for caries arrest treatment.

Additional information

Notes on contributors

Jeremy A. Horst

Jeremy A. Horst, DDS, PhD, is a fellow at the University of California, San Francisco, School of Dentistry studying the bacteria that cause cavities, a pediatric dentist at Alameda Pediatric Dentistry and co-founder and CSO at OraViz.

Conflict of Interest Disclosure: Dr. Horst is co-founder and CSO at OraViz.

Hellene Ellenikiotis

Hellene Ellenikiotis, DDS, is a resident in the University of California, San Francisco, general practice residency and a recent graduate of the University of California, San Francisco School of Dentistry.

Conflict of Interest Disclosure: None reported.

Peter L. Milgrom

Peter M. Milgrom, DDS, is a professor of dental public health sciences and pediatric dentistry and director of the Northwest Center to Reduce Oral Health Disparities at the University of Washington in Seattle.

Conflict of Interest Disclosure: Dr. Milgrom is a principal in ADP Silver Dental Arrest LLC, which licenses permission to market Advantage Arrest to Elevate Oral Care LLC.